These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 33010107)

  • 1. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
    Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
    Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
    Kim D; Koh Y; Yoon SS
    Anticancer Res; 2020 Mar; 40(3):1395-1403. PubMed ID: 32132036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series.
    Shen D; Song H; Zhang J; Liao C; Wang Y; Fang M; Tang Y
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e1-e4. PubMed ID: 33661174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.
    Reed DR; Hall RD; Gentzler RD; Volodin L; Douvas MG; Portell CA
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e247-e250. PubMed ID: 30992232
    [No Abstract]   [Full Text] [Related]  

  • 7. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
    BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alectinib for advanced
    Ly AC; Olin JL; Smith MB
    Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
    Morcos PN; Nueesch E; Jaminion F; Guerini E; Hsu JC; Bordogna W; Balas B; Mercier F
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):129-138. PubMed ID: 29748847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
    Paik J; Dhillon S
    Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
    Masuda N; Ohe Y; Gemma A; Kusumoto M; Yamada I; Ishii T; Yamamoto N
    Cancer Sci; 2019 Apr; 110(4):1401-1407. PubMed ID: 30776174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
    Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
    Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.
    Bossi E; Aroldi A; Brioschi FA; Steidl C; Baretta S; Renso R; Verga L; Fontana D; Sharma GG; Mologni L; Mussolin L; Piazza R; Gambacorti-Passerini C
    Am J Hematol; 2020 Dec; 95(12):E319-E321. PubMed ID: 32808682
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
    N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
    Ou SH; Ahn JS; De Petris L; Govindan R; Yang JC; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez SV; Mekhail T; Spira A; Bordogna W; Balas B; Morcos PN; Monnet A; Zeaiter A; Kim DW
    J Clin Oncol; 2016 Mar; 34(7):661-8. PubMed ID: 26598747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer.
    Sacdalan DB; Lucero JA
    Cancer Treat Res Commun; 2021; 27():100319. PubMed ID: 33515938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
    Fischer M; Moreno L; Ziegler DS; Marshall LV; Zwaan CM; Irwin MS; Casanova M; Sabado C; Wulff B; Stegert M; Wang L; Hurtado FK; Branle F; Geoerger B; Schulte JH
    Lancet Oncol; 2021 Dec; 22(12):1764-1776. PubMed ID: 34780709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial.
    Nagai H; Fukano R; Sekimizu M; Kada A; M Saito A; Asada R; Mori T
    Nagoya J Med Sci; 2017 Aug; 79(3):407-413. PubMed ID: 28878445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.